Repare Therapeutics (RPTX) said Maria Koehler will step down from her position as chief medical officer on March 31.

The departure is tied to the company's previously announced reorganization.

In January, the company said it would refocus its resources on advancing phase 1 clinical trials of RP-1664 and RP-3467, while seeking development partners for lunresertib and camonsertib before proceeding with further trials. If no suitable partner is found, those programs will be discontinued.

The strategic realignment, combined with cost and headcount reductions, was expected to extend the company's funds of $153 million until mid-2027.

In a recent securities filing Tuesday, Repare said it will reduce its workforce by approximately 75%, incurring one-time cash charges of about $7.3 million for severance and related costs, along with up to $1.4 million in retention expenses. These charges are expected to be incurred through the fourth quarter of 2025.

Repare expects the reorganization to result in annual operating expense savings of approximately $21 million.